Codagenix28 Jul 2020 08:54
Codagenix is a clinical-stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapy. Both programs rely on scalable, low-cost manufacturing. Codagenix Inc. spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University in 2012 and is located at the Broad Hollow Bioscience Research Park in Farmingdale, N.Y. Our programs are supported by Adjuvant Capital, TopSpin Partners, Euclidean Capital, and government agencies such as the USDA, NIH/NIAID and the Department of Defense.